ArticleCell reports2021
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 94 citations in OpenAlex.
- IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8Journal for immunotherapy of cancer · 2026Article
- CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.Targeted oncology · 2026Review
- Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling.International journal of molecular sciences · 2026Review
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
- LPAR4 mediates resistance to interferon-induced stress in soft tissue sarcoma.Science advances · 2026Article
- Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance.ACS pharmacology & translational science · 2026Review
- CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer.Oncogene · 2026Article
- CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer.Journal for immunotherapy of cancer · 2026Article
- Real-time multimodal phenotyping reveals distinct tumour cell dynamics and immune escape mechanisms in T cell therapies.Nature biomedical engineering · 2026Article
- Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Medicina (Kaunas, Lithuania) · 2026Article
- JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6.NPJ breast cancer · 2026Article
- Cyclin-dependent kinase 4 and 6 inhibitors and the breast cancer immune ecosystem: immune remodeling, resistance, and therapeutic reprogramming.Frontiers in immunology · 2026Review
- Recent Advances (2020-2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies-A Comprehensive Review.Cancer management and research · 2026Review
- The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity.Cancers · 2025Review
- Alternate actions of CDK4/6 inhibitors beyond cell cycle blockade: unexplored roles in therapy resistance.Cancer metastasis reviews · 2025Review
- IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HRNature cancer · 2025Article
- CYPD limits HRCell death discovery · 2025Article
- SNS‑032 combined with decitabine induces caspase‑3/gasdermin E‑dependent pyroptosis in breast cancer cells.Oncology letters · 2025Article
- Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer.Molecular cancer · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 5 institutions in 1 country.
Roman V UzhachenkoComprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Vijaya BhartiComprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Zhufeng OuyangComprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Ashlyn BlevinsDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
Stacey MontDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
Nabil SalehDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
Hunter A LawrenceDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA.
Chengli ShenComprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Sheau-Chiann ChenDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37212, USA.
Gregory D AyersDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37212, USA.
David G DeNardoDepartment of Medicine, Washington University St. Louis, School of Medicine, St. Louis, MO 63110, USA.
Carlos ArteagaSimmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ann RichmondDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37212, USA; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN 37212, USA.
Anna E VilgelmComprehensive Cancer Center - James, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: anna.vilgelm@osumc.edu.
The Ohio State University Wexner Medical Center · USVanderbilt University · USVanderbilt University Medical Center · USThe University of Texas Southwestern Medical Center · USWashington University in St. Louis · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MTargeting the NF-kappaB Pathway in MelanomaR01CA116021 · NCI · VANDERBILT UNIVERSITY · PI RICHMOND, ANN, YAN, CHI · 2005 to 2024
$6.7MCombining senescence-inducing and senolytic agents to improve melanoma therapyR37CA233770 · NCI · VANDERBILT UNIVERSITY · PI VILGELM, ANNA E · 2019 to 2025
$2.4MOptimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathwayR01CA243326 · NCI · VANDERBILT UNIVERSITY · PI RICHMOND, ANN, YAN, CHI · 2020 to 2024
$1.8MBLR&D Merit Review Research Career Scientist (RCS) Award (IK6)IK6BX005225 · VA · VETERANS HEALTH ADMINISTRATION · PI RICHMOND, ANN · 2020 to 2023
–Targeting IKK beta and aurora kinases in melanomaI01BX000196 · VA · VETERANS HEALTH ADMINISTRATION · PI RICHMOND, ANN · 2009 to 2013
–BLRD VA I01 BX000196BLRD VA IK6 BX005225NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA098131NCI NIH HHS R01 CA116021NCI NIH HHS R01 CA243326NCI NIH HHS R37 CA233770
Abstract
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay progression of metastatic breast cancer. However, complete responses are uncommon and tumors eventually relapse. Here, we show that CDK4/6i can enhance efficacy of T cell-based therapies, such as adoptive T cell transfer or T cell-activating antibodies anti-OX40/anti-4-1BB, in murine breast cancer models. This effect is driven by the induction of chemokines CCL5, CXCL9, and CXCL10 in CDK4/6i-treated tumor cells facilitating recruitment of activated CD8
Indexed as
AnimalsBreast NeoplasmsCell Line, TumorChemokinesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansHypertrophyImmunotherapyMammary Neoplasms, AnimalMiceMice, Inbred C57BLMitochondriaPrognosisProtein Kinase InhibitorsChemokinesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsReactive Oxygen SpeciesReceptors, ChemokineTOR Serine-Threonine Kinasesadoptive cell transferanti-tumor immunitycancer metabolismCCL5CDK4/6 inhibitorschemokinesmetabolic stresspalbociclibROS
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.